BioSpace News Archive

Horizon Therapeutics plc Named One of the 2021 Best Workplaces in Chicago™ by Great Place to Work ®

Omeros Corporation today reported that the U.S. Food and Drug Administration (FDA) will require additional time to review the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The new Prescription Drug User Fee Act (PDUFA) target action date is October 17, 2021.

Tegria today announced the acquisition of Colburn Hill Group, one of the healthcare industry’s leading developers of analytically-driven robotic process automation (RPA) technologies for revenue cycle management (RCM

Initial analysis of 400 patients from CIRCULATE-Japan study showcases Signatera’s market-leading performance with over 95% pre-surgical detection and 92% relapse sensitivity

PPD, Inc. has been recognized for excellence in the CRO Leadership Awards for the 10th consecutive year, earning praise for its clinical research capabilities and customer compatibility in a survey of pharmaceutical and biotech professionals conducted for Clinical Leader and Life Science Leader magazines.

ImmunityBio, Inc today announced an upcoming poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually this year from June 4 through June 8, 2021.

Tenaya Therapeutics, a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for TN-201, its most advanced product candidate from its proprietary Gene Therapy Platform.

Gives paramedics and EMTs rapid, secure access to life-saving medication history and secure communications with ER, doctors, and hospitals

Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in the Journal of Translational Autoimmunity describing NKTR-358, a first-in-class, composition of stable PEG conjugates of native IL-2 designed to selectively stimulate T regulatory (Treg) cell function

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021.